The devastating impact of climate change on respiratory health is a growing concern, with millions suffering from asthma attacks and lung damage due to pollution and wildfire smoke. However, the healthcare systems treating these conditions are inadvertently contributing to global warming, creating a vicious cycle.
Climate extremes and poor air quality are major drivers of respiratory diseases, with over 90% of the global population breathing air that exceeds WHO recommendations. Experts highlight the significant link between respiratory illnesses and environmental factors, such as increasing wildfires and air pollution, which exacerbate existing conditions and even trigger new ones.
Therese Laperre, a respiratory specialist, warns that climate change is intensifying triggers for asthma and chronic respiratory diseases, impacting patterns of respiratory infections. A study by the European Environment Agency estimates that over a third of chronic respiratory disease deaths in Europe are linked to environmental factors like air pollution, extreme temperatures, and allergenic pollen.
The healthcare industry's response to this burden has its own environmental cost. Health Care Without Harm estimates that global health services generate around 5% of worldwide greenhouse gas emissions, ranking them among the world's top polluters. Without intervention, healthcare emissions are projected to reach staggering levels by 2050.
Hospitals, particularly intensive care units, are major contributors to this impact due to their high energy and resource consumption. Respiratory specialists emphasize the importance of early control of chronic diseases, not only for patient well-being but also to reduce healthcare's climate footprint.
Inhalers, commonly used to treat long-term lung diseases, embody this dilemma. The most common type, pressurised metered-dose inhalers, use gas propellants with a high global warming potential. Recent estimates suggest that these inhalers contribute significantly to greenhouse gas emissions, with the UK's National Health Service estimating they account for 3% of its carbon footprint.
Efforts to reduce this environmental impact are underway, with pharmaceutical companies like AstraZeneca leading the way. Their reformulated COPD inhaler, approved in the UK and EU, has a new propellant that reduces the warming impact by 99.9%. Other major drugmakers have also committed to reducing emissions and environmental footprint.
The industry recognizes that technology and regulation play crucial roles in achieving these goals. Pharmaceutical companies aim to create a "green patient" model, where chronic diseases are well-controlled, reducing the need for emergency admissions and resource-intensive care. The final pillar is supportive regulation that facilitates innovation and low-carbon options for patients.
As we navigate this complex issue, it's clear that addressing the environmental impact of healthcare is crucial for both patient well-being and global sustainability. What steps do you think are most important to tackle this challenge? Share your thoughts in the comments!
